Trypanosomiasis Cell Models for Research

Trypanosomiasis, caused by protozoan parasites of the genus Trypanosoma, affects millions worldwide. Human African trypanosomiasis (HAT, sleeping sickness) is caused by T. brucei gambiense and T. b. rhodesiense. According to WHO, in 2020, there were 663 reported cases of HAT, a significant decline from 26,000 in 2000. American trypanosomiasis (Chagas disease), caused by T. cruzi, affects approximately 6-7 million people, mostly in Latin America, with 10,000-12,000 deaths annually (WHO, 2023). Key risk factors include poverty, poor housing, and limited access to healthcare. Without treatment, HAT is fatal; Chagas disease can lead to cardiac and digestive complications in 30-40% of chronic cases. There is no typical 5-year survival by stage as for cancers; however, acute Chagas has a mortality rate of 5-10% in symptomatic cases, and chronic Chagas reduces life expectancy by an average of 9 years (NCI, 2021).

Trypanosomiasis is an ideal model for mechanistic studies due to its well-characterized life cycle, genetic tractability of Trypanosoma brucei, and the availability of public datasets. The parasite's unique features, such as antigenic variation, glycosylphosphatidylinositol (GPI) anchor biosynthesis, and mitochondrial RNA editing, offer numerous targets. Subtypes include T. b. gambiense (chronic HAT), T. b. rhodesiense (acute HAT), and T. cruzi (Chagas). Open questions include drug resistance mechanisms, host-parasite interactions, and immune evasion. Public datasets such as TriTrypDB and GeneDB provide genomic and functional data, enabling comparative genomics and drug target identification.

Trypanosomiasis is not a carcinogenic disease; however, the parasite manipulates host signaling pathways to establish infection. Key pathways include:

• • Immune evasion via antigenic variation:

1. The variant surface glycoprotein (VSG) coat is periodically switched.

2. This prevents effective antibody responses.

• • Host cell invasion and intracellular survival (T. cruzi):

1. Parasite surface molecules (e.g., trans-sialidase) mediate attachment.

2. Activation of host PI3K/AKT pathway promotes cell entry.

• • Metabolic reprogramming:

1. Parasite alters host cell metabolism to favor its survival.

2. Induction of glycolysis and suppression of apoptosis.

• • Neuroinflammation (HAT):

1. Parasite crosses the blood-brain barrier.

2. Triggers cytokine production and neuronal damage.

Trypanosoma parasites do not typically harbor somatic mutations like cancer. However, genetic variations among strains influence virulence and drug resistance. The table below summarizes key genetic features from TriTrypDB and NCBI Gene.

Data from TriTrypDB and NCBI Gene (2023).

Trypanosoma parasites exploit host signaling networks for entry, survival, and immune evasion. Key nodes include:

• • PI3K/AKT pathway:
• • Activated by T. cruzi trans-sialidase to promote host cell invasion.
• • Inhibits apoptosis, prolonging infected cell survival.
• • MAPK/ERK pathway:
• • Induced by parasite-derived factors, enhancing cytokine production.
• • Modulates macrophage polarization.
• • cAMP signaling:
• • Parasite adenylate cyclases generate cAMP, suppressing host immune responses.
• • TGF-β signaling:
• • T. cruzi induces TGF-β, promoting fibrosis in Chagas cardiomyopathy.
• • Wnt/β-catenin:
• • Activated in T. cruzi infection, contributing to cell proliferation and migration.

Several cell lines are used to study Trypanosoma-host interactions. The table below lists common models.

Organoids derived from human cardiac or intestinal tissues are emerging as advanced models for Chagas disease, offering 3D architecture and improved physiological relevance. They enable studies of parasite invasion, persistence, and drug efficacy in a more native context.

Animal models are crucial for understanding pathogenesis and testing drugs.

• • Mouse models:
• • C57BL/6 mice infected with T. cruzi develop chronic Chagas-like disease.
• • BALB/c mice are susceptible to T. brucei, showing neurological symptoms.
• • Rat models:
• • Wistar rats infected with T. cruzi exhibit cardiac dysfunction.
• • Non-human primates:
• • Macaques infected with T. b. rhodesiense develop HAT-like syndrome.
• • Zebrafish models:
• • Transparent embryos allow real-time imaging of parasite dissemination.
• • Induced pluripotent stem cell (iPSC)-derived cardiomyocytes:
• • Human iPSC-derived cardiomyocytes infected with T. cruzi model Chagas cardiomyopathy.

These models help evaluate drug efficacy, immune responses, and disease progression.

CRISPR/Cas9 technology enables precise genetic modifications in Trypanosoma and host cells. Isogenic lines are generated by introducing specific knockouts or knock-ins, allowing functional studies. Examples include:

• • Trypanosoma brucei knockout lines:
• • AQP2 knockout to study drug resistance.
• • VSG gene knockout to investigate antigenic variation.
• • Host cell knockouts:
• • CRISPR knockout of TLR4 in macrophages to dissect innate immune signaling.
• • Knock-in of reporter genes (e.g., GFP) into the T. cruzi genome for real-time tracking.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing reproducible, validated tools. These models are engineered using CRISPR and other gene-editing technologies, ensuring consistent performance in drug discovery and functional genomics.

Gene-edited cell lines are invaluable for functional genomics in Trypanosomiasis research. Knockout lines help validate gene function:

• • AQP2 knockout in T. brucei confirms its role in pentamidine uptake.
• • Knockout of TcP2β in T. cruzi reduces virulence in mouse models.
• • CRISPR interference (CRISPRi) screens identify essential genes for parasite survival.

Knock-in lines with fluorescent tags enable live-cell imaging of parasite proteins, elucidating their localization and dynamics.

Isogenic cell lines are powerful tools for drug screening and resistance studies. By comparing wild-type and knockout lines, researchers can:

• • Identify drugs that specifically target parasite pathways.
• • Model resistance by introducing resistance-conferring mutations (e.g., AQP2 mutations).
• • Evaluate combination therapies to overcome resistance.

High-throughput screening of compound libraries against gene-edited parasites accelerates lead discovery.

CRISPR synthetic lethality screens in Trypanosoma and host cells uncover genetic vulnerabilities. For example:

• • Genome-wide knockout screens identify genes essential for parasite survival in host cells.
• • Host gene knockouts reveal pathways required for parasite entry.
• • These screens inform biomarker discovery for diagnosis and treatment monitoring.

Such approaches can pinpoint novel targets for drug development and diagnostic assays.